When machine learning is used to suggest new potential scientific insights or directions, algorithms sometimes offer solutions that are not physically sound. Subscribe to our newsletter for the latest ...

This process is costly, time-consuming, and has a low success rate. KAIST researchers have developed an AI model that, using only information about the target protein, can design optimal drug ...

As the Center for Medicare and Medicaid Innovation moves forward with additional drug-focused models, our Part D Senior ...

After walking away from cell therapy and narrowing its focus to just three modalities, Takeda is doubling down on its remaining strategic commitment by reupping a pact with AI drug designer Nabla Bio.

(RTTNews) - XtalPi (2228.HK) announced an expanded research collaboration with Pfizer (PFE) to develop a next-generation molecular modeling platform for drug discovery. The initiative aims to enhance ...

Researchers headed by teams at the Advanced Science Research Center at the CUNY Graduate Center (CUNY ASRC) and Memorial Sloan Kettering Cancer Center have developed what they describe as a ...

PARIS--(BUSINESS WIRE)--Iktos announced today the application of Iktos Artificial Intelligence technology for de novo design to selected Pfizer small-molecule discovery programs. Over the last few ...

When machine learning is used to suggest new potential scientific insights or directions, algorithms sometimes offer solutions that are not physically sound. Take, for example, AlphaFold, the AI ...